Seattle startup TwinStrand raises $50M to expand tech that identifies rare genetic mutants
May 5, 2021 at 10:55 am
Jesse Salk, CEO and co-founder of TwinStrand Biosciences. (TwinStrand Photo)
New funding: Gene-sequencing startup TwinStrand Biosciences raised $50 million in a Series B round led by Section 32, a California-based fund focused on biotech, technology, healthcare and life sciences. Total venture capital funding is now north of $70 million for the 6-year-old company.
Double strands of innovation: TwinStrand, which spun out of the University of Washington, has developed technology in both gene sequencing and analyzing sequencing results to help it find what the company calls “genetic needles in the haystack.”
The Bankers Investment Trust: Uncertain times, strong performance
Companies
The Bankers Investment Trust: Uncertain times, strong performance
Watch Alex Crooke, Fund Manager of The Bankers Investment Trust, in the Trust TV studio as he looks back on an extraordinary year for global markets and discusses the particular challenges he faced. Alex will also outline his views on the optimal global asset allocation, the outlook for dividends in 2021 and beyond, his approach to stock-picking, sector winners and losers post-COVID, and other themes relevant to the global equity investor. Click here to find out more.
References made to individual securities should not constitute or form part of any offer or solicitation to issue, sell, subscribe or purchase the security. Janus Henderson Investors, one of its affiliated advisor, or its employees, may have a position mentioned in the securities mentioned in the report. For promotional purposes. Not for onward distribution. Before investi
In association with
Watch Alex Crooke, Fund Manager of The Bankers Investment Trust, in the Trust TV studio as he looks back on an extraordinary year for global markets and discusses the particular challenges he faced. Alex also outlines his views on the optimal global asset allocation, the outlook for dividends in 2021 and beyond, his approach to stock-picking, sector winners and losers post-COVID, and other themes relevant to the global equity investor.
References made to individual securities should not constitute or form part of any offer or solicitation to issue, sell, subscribe or purchase the security. Janus Henderson Investors, one of its affiliated advisor, or its employees, may have a position mentioned in the securities mentioned in the report.
NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
NeoGenomics, Inc.: NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform
NeoGenomics exercises option struck in May 2020 to purchase remaining equity stake for $390 million
Completes $200 million strategic financing with leading oncology-focused specialist investors
FT. MYERS, FL / ACCESSWIRE / May 5, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today that it has agreed to acquire Inivata Ltd, a global, commercial stage liquid biopsy platform company headquartered in Cambridge, England. The acquisition follows a $25 million minority equity investment by NeoGenomics in Inivata in May 2020, at which time NeoGenomics was granted a fixed price option to purchase the remainder of Inivata for $390 million prior to December 31, 2021. The cash purchase price will be funded with balance sheet cash and through